期刊文献+

度洛西汀致不良反应文献分析 被引量:5

Literature analysis of adverse drug reactions induced by duloxetine
原文传递
导出
摘要 目的:分析度洛西汀所致不良反应的发生情况及临床特点,为合理用药提供参考。方法:检索Pubmed,CNKI,VIP数据库中收载度洛西汀所致不良反应文献进行统计分析,检索时间为2004-2014年7月。结果:共检索41例次不良反应报道,以女性为主(32例,78.0%),年龄分布以40-60岁多见(21例,51.2%)。度洛西汀所致不良反应累及的器官或系统较多,以肝胆系统损害最为多见(12例,29.3%),其余多见为神经和精神系统损害、内分泌紊乱、心血管系统损害等。结论:临床合理使用度洛西汀的同时,临床应警惕度洛西汀不良反应,加强监测以实现临床用药安全有效。 Objective: To analyze the situation and clinical characteristics of adverse drug reactions in- duced by duloxetine in order to provide references for rational drug use. Methods: Pubmed, CNKI and VIP data- bases were searched for adverse drug reactions (ADRs) induced by duloxetine from 2004 to July 2014, and the collected case reports were further analyzed statistically. Results: Totally 41 patients were retrieved for analysis on ADRs induced by duloxetine, among which there were 32 female patients accounting for 78.0% and 21 patients aged from 40 to 60 years old accounting for 51.2%. Multiple organs or systems were involved in ADRs induced by duloxetine, and liver and biliary system disorders were the most frequent ADRs in the collected case reports (12 patients, 29.3% ) , followed by psychiatric disorders, central and peripheral nervous system disorders, endocrine disorders, cardiac and vascular disorders. Conclusion: ADRs induced by duloxetine should be aware in rational use of duloxetine, and monitoring should be strengthened in order to realize safe and effective use in the clinical context.
出处 《中国新药杂志》 CAS CSCD 北大核心 2014年第22期2701-2704,共4页 Chinese Journal of New Drugs
基金 临床药学科国家临床重点专科建设项目
关键词 度洛西汀 药物不良反应 文献分析 duloxetine adverse drug reaction literature analysis
  • 相关文献

参考文献23

  • 1DHILLON S. Duloxetine : a review of its use in the managementof major depressive disorder in older adults [ J ]. Drugs Aging,2013,30( 1 ) :59 -79.
  • 2LOBO ED, QUINLAN T, O’BRIEN L,et al. Population phar-macokinetics of orally administered duloxetine in patients : impli-cations for dosing recommendation [ J ]. Clin Pharmacokinet,2009,48(3) :189 - 197.
  • 3VUPPALANCHI R, HAYASHI PH, CHALASANI N, et al. Du-loxetine hepatotoxicity : a case-series from the drug-induced liverinjury network [ J ]. Aliment Pharmacol Ther, 2010, 32 ( 9 ):1174 - 1183.
  • 4HANJE AJ, PELL LJ, VOTOLATO NA, et al. Case report; ful-minant hepatic failure involving duloxetine hydrochloride [ J ].Clin Gastroenterol Hepatol, 2006 ,4(7) :912 - 917.
  • 5PARIKH AR, THATCHER BT, TAMANO EA, et al. Suicidal i-deation associated with duloxetine use : a case series[ J] . J ClinPsychopharmacol, 2008 ,28 (1 ) : 101 - 102.
  • 6PERITOGIANNIS V, ANTONIOU K, MOUKA V,et al. Duloxe-tine-induced hypomania : case report and brief review of the liter-ature on SNRIs-induced mood switching [ J ] . J Psychopharmacol,2009,23(5) ;592 -596.
  • 7JUURLINK DN, MAMDANI MM, KOPP A, et al. The risk ofsuicide with selective serotonin reuptake inhibitors in the elderly[J] . Am J Psychiatry, 2006,163 :813 - 821.
  • 8GELENER P,GOHGULU U, KUTLU G, et al. Serotonin syn-drome due to duloxetine [ J ] . Clin Neuropharmacol, 2011,34(3):127 -128.
  • 9ALBAYRAK Y , EKINCI O. Duloxetine-associated tardive dyski-nesia resolved with fluvoxamine ; a case report [ J ] - J Clin Psy-chopharmacol ,2012,32(5) :723 -724.
  • 10GARTLEHNER G, THALER K,HANSEN RA,et al. The gen-eral and comparative efficacy and safety of duloxetine in major de-pressive disorder: a systematic review and meta-analysis [ J ].Drug Saf, 2009,32(12) :1159 - 1173.

二级参考文献13

  • 1BRECHT S, DESAIAH D, MARECHAL ES, et al. Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospital- ized for severe depression: a double-blind randomized trial[ J]. J Clin Psychiatry, 2011, 72(8) :1086 -1094.
  • 2GARTLEHNER G, THALER K, HANSEN RA, et al. The gen- eral and comparative efficacy and safety of duloxetine in major de- pressive disorder: a systematic review and meta-analysis [J]. Drug Saf, 2009, 32(12) :1159 -1173.
  • 3PERAHIA DG, MAINA G, THASE ME, et al. Duloxetine in the prevention of depressive recurrences: a randomized, double- blind, placebo-controlled trial[J]. J Clin Psychiatry, 2009,70 (5) : 706 -716.
  • 4MANCINI M, GIANNI W, ROSSI A, et al. Duloxetine in the management of elderly patients with major depressive disorder: an analysis of published data[ J]. Expert Opin Pharmacother, 2009, 10(5) : 847 -860.
  • 5喻东山;葛茂宏.精神科合理用药手册[M]南京:江苏科学技术出版社,2011210-223.
  • 6Englisch S,Fritzinger M,Zink M. Urinary retention during combined treatment of postpsychotic depression with duloxetine and olanzapine[J].Clinical Neuropharmacology,2008,(05):307-309.doi:10.1097/WNF.0b013e318157e462.
  • 7高成阁,王刚,许秀峰,谢世平,谭庆荣,杜波,程能能,王崴,陈策,伏炜,杨小波,亢万虎,李强,马现仓.度洛西汀肠溶胶囊治疗抑郁症的多中心随机双盲对照临床研究[J].中国新药与临床杂志,2008,27(7):481-485. 被引量:46
  • 8钱敏才,林敏,沈鑫华,钟华,朱毅平,杨剑虹.度洛西汀与文拉法辛对首发抑郁症疗效的对照研究[J].上海精神医学,2008,20(5):292-294. 被引量:32
  • 9彭江发,冯征,叶小英,顾雯.度洛西汀与西酞普兰治疗不同症状抑郁症的对照研究[J].精神医学杂志,2009,22(2):94-95. 被引量:6
  • 10许律琴.度洛西汀与艾司西酞普兰治疗女性抑郁症疗效的对照研究[J].上海精神医学,2009,21(3):166-168. 被引量:25

共引文献7

同被引文献76

  • 1李一云,季建林.文拉法辛与米氮平治疗抑郁症的临床比较分析[J].上海精神医学,2003,15(6):358-360. 被引量:23
  • 2赵静,朱珠.治疗重症抑郁和糖尿病周围神经病变的新药——度洛西汀[J].中国药学杂志,2006,41(14):1118-1120. 被引量:8
  • 3喻东山.内科中的惊恐障碍[J].临床精神医学杂志,2007,17(5):354-355. 被引量:7
  • 4Eaton WW, Kessler RC, Wittchen HU, et al. Panic and panic disorder in the United State [ J]. Am J Psychiatry, 1994,151 (3) :413 -420.
  • 5Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age - of - onset distributions of DSM - IV disorders in theNational Comorbidity Survey Replication [ J]. Arch Gen Psychi- atry, 2005, 62(6):593-602.
  • 6Simon NM, Fischmann D. The implications of medical and psy- chiatric comorbidity with panic disorder [ J]. J Clin Psychiatry, 2005,66( Suppl 4) :8 - 15.
  • 7Waiters K, Rait G, Petersen I. Panic disorder and risk of new onset coronary heart disease, acute myocardial infarction, and cardiac mortality: cohort study using the general practice re- search database [J]. European Heart Journal, 2008,29(24) : 2 981 - 2 988.
  • 8Henkel V, Seemuller F, Obermeier M, et al. Does early im- provement triggered by antidepressants predict response/remis- sion? Analysis of data fore a naturalistic study on a large sample of inpatients with major depression [J]. J Affect Disord, 2009, 115(3) :439 -449.
  • 9Gourion D, Galinowski A, Baraille L, et al. Switch antidepres- sants: when.? How? Why? [J]. Encephale, 2011, 37 (Suppl 1) :S50 -S57.
  • 10WHO. The world health report 2001 - Mental health: new un- derstanding, new hope [ EB/OL] . http://www, who. int/ whr/ 2001/ err/.

引证文献5

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部